Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.

Samuel Dagogo-Jack Richard E PratleyDavid Z I CherneyDarren K McGuireFrancesco CosentinoWeichung J ShihJie LiuRobert FrederichJames P MancusoAnnaswamy RajiIra Gantz

Published in: BMJ open diabetes research & care (2021)

NCT01986881.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
glycemic control
peritoneal dialysis
skeletal muscle